Business
Medicenna to Present Latest Data from the MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress
Medicenna to Present Latest Data from the MDNA55 Clinical Trial in Recurrent Glioblastoma ...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna to Present Latest Data from the MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen3{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnvat{\nVERTICAL-ALIGN: TOP\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prnsblb0{\nBORDER-LEFT:black 0pt\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnrbrb0{\nBORDER-RIGHT:black 0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbtb0{\nBORDER-TOP:black 0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, Sept. 12, 2019\n\n\n\nTORONTO and HOUSTON, Sept. 12, 2019 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it will present updated clinical results from the Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma (rGBM) at the Inaugural Targeting Innate Immunity Congress to be held on September 24 and 25, 2019 in Cambridge, MA.\nThe presentation will discuss recent clinical data on survival outcomes and therapeutic benefit from MDNA55 in rGBM patients, a uniformly fatal type of brain cancer. Medicenna's lead candidate, MDNA55, simultaneously targets the interleukin-4 receptor (IL-4R), which is over-expressed by tumor cells and its supportive tumor microenvironment (TME) which hides the tumor from the immune system. \nThe details of the podium presentation are as follows:\nTitle:\nTipping the balance towards success in a Phase 2b recurrent GBM Trial: Overcoming the tumor and its microenvironment by targeting the IL4R using MDNA55\nPresenter:\nDr. Fahar Merchant, PhD\nDate/Time:\nWednesday, September 25, 2019 at 10:00 am\nLocation:\nHyatt Regency Cambridge, 575 Memorial Drive, Cambridge, MA 02139\n \nAbout Medicenna Therapeutics Corp.Medicenna is a clini...